CTKB vs DHR
CTKB: Cytek Biosciences sells spectral flow cytometry instruments and integrated cell analysis platforms powered by patented Full Spectrum Profiling technology that enable high-resolution, high-dimensional single-cell analysis for biomedical research and clinical applications. DHR: Danaher is a diversified conglomerate providing scientific instruments, diagnostics, and industrial solutions across life sciences, environmental monitoring, product identification, and healthcare globally.
Side-by-side fundamentals
| Metric | CTKB | DHR | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $4.54 | $179.14 | |
| Market cap as of 2026-07-23 | $586M | $125.9B | |
| P/E as of 2026-07-23 | n/a | 34.12 | |
| PEG as of 2026-07-23 | -0.01 | 3.97 | CTKB lower |
| Net margin as of 2026-07-23 | -36.3% | +14.9% | DHR higher |
| Gross margin as of 2026-07-23 | +51.7% | +59.0% | DHR higher |
| Operating margin as of 2026-07-23 | -21.5% | +19.2% | DHR higher |
| ROE as of 2026-07-23 | -20.8% | +7.1% | DHR higher |
| ROA as of 2026-07-23 | -15.6% | +4.5% | DHR higher |
| Debt / equity as of 2026-07-23 | 0.03 | 0.35 | CTKB lower |
| Revenue growth (YoY) as of 2026-07-23 | +3.6% | +4.0% | DHR higher |
| Revenue CAGR (3y) SEC XBRL | +7.1% | -2.7% | CTKB higher |
| Dividend yield as of 2026-07-23 | n/a | +0.9% | |
| Beta as of 2026-07-23 | 1.17 | 0.78 | |
| 1-year return as of 2026-07-22 close | +47.4% | -5.7% | CTKB higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.